Transcranial Magnetic Stimulation (TMS) has accumulated robust clinical evidence supporting its effectiveness, particularly in major depressive disorder (MDD). Multiple high-quality randomized controlled trials and meta-analyses demonstrate that active TMS significantly outperforms sham treatments. An umbrella meta-analysis published in 2023 found that patients undergoing TMS had over three times the odds of achieving clinical response or remission compared to placebo groups (Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depression, Schizophrenia, and Obsessive-Compulsive Disorder: An Umbrella Meta-Analysis).

Real-world outcomes further validate these findings. A large post-marketing study involving 1,351 patients with treatment-resistant depression (many of whom had failed multiple medications) reported that 82% experienced a response (defined as =50% symptom reduction), and 65% achieved full remission following a standard TMS course (BrainsWay Post-Marketing Study Confirms Substantial Clinical Benefits of Deep TMS™ in Treating Depression and Anxious Depression).

Notably, accelerated TMS protocols are showing rapid and powerful results. The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) protocol, involving high-dose intermittent theta-burst stimulation over five days, led to remission in 79% of highly treatment-resistant patients (FDA Clears SAINT Rapid-Acting Brain Stimulation Approach for Those Suffering From Resistant Major Depression|Brain & Behavior Research Foundation). Similarly, an accelerated deep TMS protocol involving multiple sessions per day achieved an 80% response rate and a 51% remission rate—comparable to six-week courses but completed within days (BrainsWay Announces Publication of Study Data on Accelerated Deep Transcranial Magnetic Stimulation (Deep TMS™) for Depression). These results underscore the expanding capabilities of TMS as a fast-acting and effective treatment for depression.

Recent FDA Approvals and Expanded Indications

Since its initial approval in 2008, the U.S. Food and Drug Administration (FDA) has broadened TMS applications across a range of neuropsychiatric conditions. Key milestones include:

  • 2008: The first FDA clearance for TMS was granted for treatment-resistant depression in adults using the NeuroStar system.

  • 2013: BrainsWay’s deep TMS system received approval for depression, while the eNeura sTMS was approved for migraine pain.

  • 2018: The FDA approved deep TMS (H7 coil) as an adjunct for adult Obsessive-Compulsive Disorder (OCD), marking the first psychiatric use beyond depression.

  • 2018–2019: The introduction of theta burst stimulation (TBS) protocols allowed for treatment times as short as 3 minutes per session, increasing convenience and accessibility.

  • 2020: BrainsWay’s H4 coil system was approved for short-term smoking cessation in adults, and additional systems were cleared for OCD.

  • 2021: TMS received approval for treating anxious depression—depression accompanied by anxiety symptoms.

  • 2022: The SAINT protocol became the first FDA-approved rapid-acting TMS therapy for treatment-resistant depression.

  • 2023: NeuroStar’s TMS system was cleared for use in adolescents (ages 15–21) with MDD, marking the first approval in younger patients.

These regulatory milestones signify the mainstream acceptance of TMS for a wide spectrum of psychiatric and neurological disorders. TMS is now covered by most insurance providers, including Medicare, making it more accessible to the public (FDA Clears Magstim Horizon INSPIRE Transcranial Magnetic).

Advances in Deep TMS Technology (BrainsWay)

BrainsWay’s introduction of Deep TMS has been transformative in expanding the clinical potential of brain stimulation. Unlike traditional TMS coils, which only reach superficial cortical areas, BrainsWay’s patented H-coils can penetrate deeper brain regions. These coils, housed in a helmet-like apparatus, stimulate broader and deeper neural circuits.

For example, the H7 coil targets the medial prefrontal cortex and anterior cingulate cortex—key regions involved in OCD. Comparative electric field mapping shows that H-coils stimulate up to five times more brain volume than figure-8 coils (Detailed measurements and simulations of electric field distribution of two TMS coils cleared for obsessive compulsive disorder in the brain and in specific regions associated with OCD – PMC).

BrainsWay has developed multiple H-coils tailored to specific disorders: the H1 coil for MDD, the H7 coil for OCD, and the H4 coil for smoking cessation. The ability to match coil design to specific neuroanatomical targets has enabled TMS to treat disorders previously beyond reach. Clinical trials have validated deep TMS’s efficacy across its cleared indications, further reinforcing its technological superiority.

Current research focuses on optimizing protocols through MRI-guided targeting and accelerating outcomes with high-frequency or multi-session daily treatments. BrainsWay is also exploring additional indications such as PTSD and neurorehabilitation, which have received CE approval in Europe. These innovations position deep TMS as a flexible and powerful platform in modern psychiatry.

TMS vs. Traditional Treatments (Medications)

When compared to pharmacological treatments, TMS offers distinct advantages, particularly for individuals with treatment-resistant conditions. Antidepressant efficacy often diminishes after multiple failed trials. In contrast, TMS has demonstrated strong results even in patients who have failed numerous medications.

For example, in a study of patients who had failed an average of seven antidepressant medications, over 80% responded to TMS therapy (BrainsWay Post-Marketing Study). Other head-to-head studies suggest TMS can outperform medication strategies in patients with chronic depression (Transcranial Magnetic Stimulation for Alcohol Cravings|Psychology Today).

TMS also presents a more favorable side effect profile. Because it is non-systemic, it avoids many of the common adverse effects associated with antidepressants, such as weight gain, sedation, and sexual dysfunction. The most frequent side effects—scalp discomfort or mild headache—are temporary and well-tolerated. Seizures are exceedingly rare, occurring in less than 0.1% of patients, and proper screening protocols ensure safety (International OCD Foundation).

Unlike electroconvulsive therapy (ECT), which requires anesthesia and often causes memory issues, TMS is non-invasive, conducted on an outpatient basis, and generally free of cognitive side effects. Patients remain alert and can return to their daily routines immediately following treatment.

TMS may be used as a monotherapy or in conjunction with medications and psychotherapy. Its structured delivery model (typically daily sessions over 4–6 weeks) supports high adherence, and the effects can be long-lasting, often requiring only occasional maintenance sessions.

Broadening Applications Beyond Depression: OCD, PTSD, Addiction, and More

Obsessive-Compulsive Disorder (OCD)

TMS, especially deep TMS, has become a groundbreaking therapy for OCD. FDA approval in 2018 was based on strong evidence that stimulation of the anterior cingulate cortex reduces OCD symptoms. About 45–55% of patients experience clinically meaningful improvement after one month of TMS treatment.

The “provocation” method—having patients engage with their OCD triggers during sessions—has been shown to enhance the treatment’s effect. This integrated approach has led to sustained improvements for many patients and is now used in TMS clinics worldwide.

Post-Traumatic Stress Disorder (PTSD)

TMS has shown promise for PTSD, though it remains off-label in the U.S. Controlled studies have demonstrated that TMS can significantly reduce PTSD symptoms, including intrusive thoughts, mood disturbances, and sleep problems. High-frequency stimulation to the right dorsolateral prefrontal cortex appears particularly effective.

A trial of deep TMS in 99 Israeli veterans showed that 44% had significant symptom improvement at six months, along with reduced depression and suicidal ideation (Israel Ministry of Defense Clears BrainsWay Deep TMS™ for PTSD Reimbursement). These findings have prompted regulatory adoption in Israel and may lay the groundwork for future FDA approvals.

Addiction and Substance Use Disorders

TMS has entered the field of addiction treatment with FDA approval for smoking cessation in 2020. Deep TMS using the H4 coil has demonstrated efficacy in reducing cravings and helping smokers quit, especially when combined with counseling.

Beyond nicotine, early studies in alcohol use disorder have found that TMS reduces cravings and drinking frequency. One review concluded that TMS offers moderate but clinically meaningful benefits in reducing alcohol-related behaviors (Transcranial Magnetic Stimulation for Alcohol Cravings|Psychology Today). Pilot studies for cocaine and methamphetamine use have shown reduced cravings and increased abstinence duration, although more research is needed.

The neuromodulatory effects of TMS on the brain’s reward circuits may make it a valuable addition to standard addiction therapies, particularly for individuals resistant to traditional treatments.

Other Emerging Applications

Researchers are investigating TMS across a variety of other conditions. These include:

  • Generalized anxiety disorder

  • Panic disorder

  • Bipolar depression

  • Schizophrenia (particularly negative symptoms and hallucinations)

  • Fibromyalgia and other chronic pain syndromes

  • Autism spectrum disorder

  • ADHD

  • Alzheimer’s disease

For example, low-frequency TMS to the right prefrontal cortex has shown anxiolytic effects in generalized anxiety disorder, while stimulation of the temporoparietal area in schizophrenia patients has led to moderate reductions in hallucinations.

TMS has also been approved for migraine treatment with the eNeura portable device, which interrupts acute attacks in patients with aura. Studies are ongoing to explore optimal stimulation parameters for each condition, which include target location, pulse frequency, session duration, and course length.

Get the Care you Deserve

Transcranial Magnetic Stimulation has evolved from a niche therapy for treatment-resistant depression into a versatile neuromodulation platform with a growing list of applications. Advances in technology, especially through Deep TMS, have extended its reach into previously inaccessible brain regions. Accelerated protocols are reducing treatment times while maintaining or enhancing efficacy. Compared to traditional medications, TMS offers strong efficacy and a more favorable side effect profile, particularly in populations that are difficult to treat.

As evidence accumulates and FDA approvals expand, TMS is poised to play a central role in the future of psychiatric and neurological care. It offers new hope for patients with OCD, PTSD, addiction, and many other conditions, bridging the gap between neuroscience and compassionate care.

Request Appointment|TMS Therapy|Serenity Mental Health Centers

This content is for informational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider.